Business & Industry
Roche and Earendil Forge $1.5 Billion Bispecific Antibody Discovery Deal
Roche-owned Genentech has entered into a major collaboration with Earendil Labs to discover and develop bispecific antibodies targeting oncology, in a deal valued at up to $1.5 billion.
Deal Structure and Financial Terms
Under the terms of the agreement, Earendil will...
Business & Industry
AbbVie and Iambic Partner to Accelerate AI Drug Discovery in Immunology, Neuroscience and Oncology
AbbVie and Iambic have entered into a multiyear collaboration focused on AI drug discovery across three major therapeutic areas — immunology, neuroscience, and oncology. The partnership brings together Iambic's molecular superintelligence platform and AbbVie's established drug discovery expertise, with...
Business & Industry
Treatment for Rare Disease cALD Approved by European Commission
Neuraxpharm and Minoryx Therapeutics have secured European Commission approval for Nezglyal (leriglitazone), making it the first approved drug therapy for rare disease cALD — cerebral adrenoleukodystrophy — in the European Union, with a commercial launch expected before the end...
Business & Industry
FDA Advisory Panel Votes in Favour of GRAIL Galleri Multi-Cancer Early Detection Test
A United States Food and Drug Administration advisory panel has voted in favour of approving GRAIL's Galleri, positioning the multi-cancer early detection test for a potential landmark regulatory decision in the months ahead.
Panel Votes Across Three Key Dimensions
The ten...
Business & Industry
InnoCare Pharma Signs $3.35 Billion Strategic Licensing Agreement with Eli Lilly
Chinese biopharmaceutical company InnoCare Pharma has entered into a strategic research collaboration and licensing agreement with Eli Lilly and Company to develop new medicines, with total potential payments reaching approximately $3.35 billion.
Agreement Structure and Financial Terms
Under the terms of...
News
How Tamper-Evident Packaging Protects Pharmaceutical Supply Chains: Case Studies in Brand Protection
Counterfeit pharmaceuticals represent one of the most dangerous threats facing the healthcare industry today. These fake medications endanger patient lives, drain revenue from legitimate manufacturers and undermine trust in pharmaceutical brands. Protecting your supply chain requires more than standard...
Business & Industry
Novartis and BoomRay Enter Global License Agreement for Preclinical Radioligand Therapy Asset
Novartis has entered into an exclusive global license agreement with BoomRay Pharmaceuticals for an undisclosed preclinical radioligand therapy asset, with total potential payments to BoomRay reaching up to $900 million.
Announced on September 22, 2026, this radioligand license deal brings...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read